-+ 0.00%
-+ 0.00%
-+ 0.00%

DBV Technologies targets Q3 2026 BLA filing for VIASKIN Peanut Patch in children aged 4-7 years

PUBT·06/29/2026 23:12:44
Listen to the news
DBV Technologies targets Q3 2026 BLA filing for VIASKIN Peanut Patch in children aged 4-7 years
  • DBV Technologies delayed its planned BLA filing for the Viaskin Peanut Patch in peanut-allergic children aged 4 to 7 to Q3 2026.
  • No clinical trial results were presented in the update, with the focus on preparing the submission package for FDA review.
  • FDA feedback centered on how existing manufacturing and statistical data are organized, which DBV expects to support a smoother review.
  • The agency did not request additional data, lowering the risk of new studies before the filing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.